ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ENGN ENGENE HOLDINGS INC

Not Yet Opened 10-21 16:00:00 EDT

1.63

-0.04

-2.40%

盘后1.63

+0.000.00%

19:30 EDT

High1.68	Low1.59	Vol1.11M
Open1.68	D1 Closing1.67	Amplitude5.45%
Mkt Cap109.18M	Tradable Cap53.35M	Total Shares66.98M
T/O1.80M	T/O Rate3.39%	Tradable Shares32.73M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ENGN","market":"US","secType":"STK","nameCN":"ENGENE HOLDINGS INC","latestPrice":1.63,"timestamp":1792612800000,"preClose":1.67,"halted":0,"volume":1108892,"hourTrading":{"tag":"盘后","latestPrice":1.63,"preClose":1.63,"latestTime":"19:30 EDT","volume":38,"amount":62.32,"timestamp":1792625405746,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.023952095808383256,"floatShares":32731400,"shares":66984661,"eps":-2.020468,"marketStatus":"Not Yet Opened","change":-0.04,"latestTime":"10-21 16:00:00 EDT","open":1.68,"high":1.681,"low":1.59,"amount":1803936.7453532,"amplitude":0.054491,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.020468,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1792656000000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.67,"preHourTrading":{"tag":"盘前","latestPrice":1.69,"preClose":1.67,"latestTime":"08:57 EDT","volume":299,"amount":494.5307211,"timestamp":1792587429699,"change":0.02,"changeRate":0.011976,"amplitude":0.071856},"postHourTrading":{"tag":"盘后","latestPrice":1.63,"preClose":1.63,"latestTime":"19:30 EDT","volume":38,"amount":62.32,"timestamp":1792625405746,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.069514,"impliedVol":1.5103,"impliedVolPercentile":0.5755},"requestUrl":"/m/hq/s/ENGN/wiki","defaultTab":"wiki","newsList":[{"id":"2675351364","title":"enGene to Host KOL Webinar on High-Risk NMIBC Treatment Decisions and Legend Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2675351364","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675351364?lang=en_us&edition=fundamental","pubTime":"2026-10-13 20:00","pubTimestamp":1791892844,"startTime":"0","endTime":"0","summary":"enGene to host KOL webinar on high-risk NMIBC treatment decisions and LEGEND trial dataenGene will host a KOL webinar on Oct. 15, 2026 at 10:00 a.m. ET.Agenda includes preclinical data supporting a po","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nNDL8tNWBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670180354","title":"enGene Interim CMO William Grossman Acquires Common Shares Worth $10,050.94","url":"https://stock-news.laohu8.com/highlight/detail?id=2670180354","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670180354?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:41","pubTimestamp":1790282467,"startTime":"0","endTime":"0","summary":"enGene interim CMO William Grossman acquires common shares worth $10,050.94William Grossman, interim chief medical officer, bought 5,102 enGene Therapeutics common shares at USD 1.97 each.Post-transac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260924:nNDL85RZzy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"enGene Interim CMO William Grossman Acquires Common Shares Worth $10,050.94","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533881","title":"enGene Therapeutics Inc. Reports Results for the Quarter Ended July 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533881","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533881?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:25","pubTimestamp":1788956748,"startTime":"0","endTime":"0","summary":"enGene Therapeutics Inc. reports results for the quarter ended July 31 - Earnings SummaryenGene Therapeutics Inc.ENGN.OQreported a quarterly adjusted loss of 47 cents per share for the quarter ended J","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL8N45119T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666275371","title":"Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666275371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666275371?lang=en_us&edition=fundamental","pubTime":"2026-09-09 00:40","pubTimestamp":1788885608,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on enGene Holdings (ENGN) and Structure Therapeutics, I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-engene-holdings-engn-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-engene-holdings-engn-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GPCR","SAPH","LU0128526141.USD","AADR","ENGN","BK4585","CVY","DINT","BK4588","BK4137","LABU","ARMH","DIVL","XBI","BK4007","HCSG","BK4599","BK4581","LU0029874061.USD","XLV","APIE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327243","title":"enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327243","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327243?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:42","pubTimestamp":1788867737,"startTime":"0","endTime":"0","summary":"enGene Holdings (NASDAQ:ENGN) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 17.54 percent increase over losses of $(0.57) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/61654252/engene-holdings-q3-eps-0-47-misses-0-43-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327605","title":"enGene Q3 FY26 Net Loss Widens 12.11% to USD 32.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327605","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327605?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:31","pubTimestamp":1788867093,"startTime":"0","endTime":"0","summary":"enGene Q3 FY26 net loss widens 12.11% to USD 32.5 millionenGene posted a Q3 net loss attributable to common shareholders of USD 32.5 million, or USD 0.47 a share.Loss widened from USD 29 million a yea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL87wnD7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665327685","title":"enGene Reports Third Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2665327685","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665327685?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:30","pubTimestamp":1788867001,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUA9XXQVZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665316756","title":"enGene Therapeutics Inc. Expected to Post a Loss of 43 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2665316756","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665316756?lang=en_us&edition=fundamental","pubTime":"2026-09-07 19:01","pubTimestamp":1788778912,"startTime":"0","endTime":"0","summary":"enGene Therapeutics Inc. <ENGN.OQ> expected to post a loss of43cents a share - Earnings PreviewenGene Therapeutics Inc.ENGN.OQENGN.Ois expected to  show no change in quarterly revenue when it reports ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260907:nL8N44Z0ND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664285915","title":"enGene Therapeutics to Present at Wells Fargo Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285915","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285915?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:30","pubTimestamp":1788265849,"startTime":"0","endTime":"0","summary":"enGene Therapeutics to Present at Wells Fargo Healthcare ConferenceenGene will join investor conferences in September 2026, including fireside chats at Wells Fargo on Sept. 8.Management is also schedu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDLb1wLFy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653981597","title":"Engene Therapeutics Files Form 3 for SVP Finance, Treasurer Kathleen P. Richton","url":"https://stock-news.laohu8.com/highlight/detail?id=2653981597","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653981597?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:06","pubTimestamp":1784750785,"startTime":"0","endTime":"0","summary":"enGene Therapeutics files Form 3 for SVP Finance, Treasurer Kathleen P. RichtonenGene Therapeutics named SVP Finance, Treasurer Kathleen P. Richton as a holder of 6,900 common shares, mostly via stock","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL4zY1NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651441195","title":"Engene Therapeutics - Richard Glickman Resigns as Director and Chairman of Engene Therapeutics - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2651441195","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651441195?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:07","pubTimestamp":1784203678,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nFWN43I0R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651441935","title":"Engene Names Michael Heffernan Board Chairman as Richard Glickman Steps Down","url":"https://stock-news.laohu8.com/highlight/detail?id=2651441935","media":"Reuters","labels":["executive","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651441935?lang=en_us&edition=fundamental","pubTime":"2026-07-16 20:03","pubTimestamp":1784203390,"startTime":"0","endTime":"0","summary":"enGene names Michael Heffernan board chairman as Richard Glickman steps downenGene named Michael Heffernan chairman, replacing Dr. Richard Glickman, who is stepping down after more than 14 years in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL6pZVZ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COLL","BK4007","BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651465927","title":"Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2651465927","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651465927?lang=en_us&edition=fundamental","pubTime":"2026-07-15 21:00","pubTimestamp":1784120407,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA4ZJ7X0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GERN","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644036936","title":"enGene amends filing, lifts estimated non-cash stock-comp restructuring charge to $4.7 million-$5 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2644036936","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644036936?lang=en_us&edition=fundamental","pubTime":"2026-06-19 04:07","pubTimestamp":1781813232,"startTime":"0","endTime":"0","summary":"enGene filed an amended 8-K to update restructuring charges tied to its June 14 plan to cut about 50% of its workforce.Added performance-based equity retention awards, lifting expected non-cash stock-based compensation tied to the restructuring to USD 4.7 million-USD 5 million.Projected restructuring cash costs unchanged at USD 5.7 million-USD 6.4 million, mainly severance and benefits; most charges still expected in 2H 2026.Estimated retention costs now include up to USD 1.7 million cash, up to USD 2.8 million non-cash compensation linked to milestone-based vesting.CEO Ronald Cooper received a 400,000-share performance-based option at USD 1.75, vesting on BLA acceptance by Sep. 30, 2027 and FDA approval by Dec. 31, 2028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL6Fvl96:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644033202","title":"EnGene Shares Fall After Morgan Stanley Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2644033202","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644033202?lang=en_us&edition=fundamental","pubTime":"2026-06-19 03:10","pubTimestamp":1781809808,"startTime":"0","endTime":"0","summary":"EnGene (ENGN) shares fell 1.4% in Thursday trading after Morgan Stanley downgraded the stock to underweight from equalweight.Trading volume stood at over 735,000 shares compared with a daily average of nearly 1.6 million.Price: 1.72, Change: -0.02, Percent Change: -1.44","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644125085","title":"enGene Detalimogene's Durability Profile 'Not Competitive,' Morgan Stanley Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2644125085","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644125085?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:45","pubTimestamp":1781786706,"startTime":"0","endTime":"0","summary":"enGene (ENGN) is experiencing \"reduced confidence\" from physicians that the company's LEGEND clinical trial to treat patients with non-muscle invasive bladder cancer would support significant adoption","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644026337","title":"Morgan Stanley Downgrades enGene to Underweight From Equalweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2644026337","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644026337?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:18","pubTimestamp":1781777937,"startTime":"0","endTime":"0","summary":"enGene Holdings (ENGN) has an average rating of hold and mean price target of $6.85, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643756302","title":"enGene Holdings Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2643756302","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643756302?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:29","pubTimestamp":1781605740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ENGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2026 06:29 ET (10:29 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643206023","title":"Engene Reports Second Quarter 2026 Financial Results And Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2643206023","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643206023?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:28","pubTimestamp":1781530136,"startTime":"0","endTime":"0","summary":"June 15 (Reuters) - enGene Therapeutics Inc ::*ENGENE REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE*ENGENE THERAPEUTICS - IMPLEMENTS WORKFORCE REDUCTION OF ABOUT 50% IN JU","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nRSD7wj98j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ENGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643820617","title":"enGene Therapeutics - Estimates $5.7-$6.4 Mln Restructuring Costs and $4.7-$5 Mln Non-Cash Stock Compensation - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643820617","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643820617?lang=en_us&edition=fundamental","pubTime":"2026-06-15 21:17","pubTimestamp":1781529459,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42N02H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ENGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.engene.com","stockEarnings":[{"period":"1week","weight":0.0449},{"period":"1month","weight":-0.1684},{"period":"3month","weight":-0.1376},{"period":"6month","weight":-0.796},{"period":"1year","weight":-0.8082},{"period":"ytd","weight":-0.8195}],"compareEarnings":[{"period":"1week","weight":0.0045},{"period":"1month","weight":-0.0005},{"period":"3month","weight":0.0473},{"period":"6month","weight":0.0829},{"period":"1year","weight":0.1516},{"period":"ytd","weight":0.1337}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.029235},{"month":2,"riseRate":0.666667,"avgChangeRate":0.279751},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.143944},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.023431},{"month":5,"riseRate":0,"avgChangeRate":-0.421721},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.014713},{"month":7,"riseRate":1,"avgChangeRate":0.027771},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.006111},{"month":9,"riseRate":0.666667,"avgChangeRate":0.17029},{"month":10,"riseRate":0.666667,"avgChangeRate":0.070515},{"month":11,"riseRate":0.5,"avgChangeRate":0.04834},{"month":12,"riseRate":0.666667,"avgChangeRate":0.030902}],"exchange":"NASDAQ","name":"ENGENE HOLDINGS INC","nameEN":"ENGENE HOLDINGS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ENGENE HOLDINGS INC,ENGN,ENGENE HOLDINGS INC股票,ENGENE HOLDINGS INC股票老虎,ENGENE HOLDINGS INC股票老虎国际,ENGENE HOLDINGS INC行情,ENGENE HOLDINGS INC股票行情,ENGENE HOLDINGS INC股价,ENGENE HOLDINGS INC股市,ENGENE HOLDINGS INC股票价格,ENGENE HOLDINGS INC股票交易,ENGENE HOLDINGS INC股票购买,ENGENE HOLDINGS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ENGENE HOLDINGS INC(ENGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ENGENE HOLDINGS INC(ENGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction